Civitas Therapeutics Obtains $20,000,000 Series A Funding
- Feed Type
- Link
http://www.venturedeal.com/Search/SearchResultTransactionDetail.aspx?TransactionId=ef17d034-98ac-4785-bd29-5c55545dcc39&Preview=1 - Date
1/10/2011 - Company Name
Civitas Therapeutics - Mailing Address
190 Everett Ave. Chelsea, MA 02150 - Company Description
Civitas is a privately held pharmaceutical company focused on developing products with a clinically proven dry powder pulmonary delivery platform. The proprietary dry powder and device combination is unique in its ability to deliver a large, precise dose independent of inspiratory flow rate from a simple, passive device. - Website
http://www.civitastherapeutics.com - Transaction Type
Venture Equity - Transaction Amount
$20,000,000 - Transaction Round
Series A - Proceeds Purposes
The proceeds of the financing will be primarily used to advance Civitas’ lead program for treating patients with Parkinson’s disease through clinical proof-of-concept. The company is a spin-out of Alkermes, Inc.’s pulmonary delivery business that includes the related technology, pipeline assets and the commercial ready manufacturing facility. - M&A Terms
- Venture Investor
Longitude Capital Management - Venture Investor
Canaan Partners
